Reply to comments by Dr Peng et al for "pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection"

Journal of Clinical Psychopharmacology

Volumn 28, Issue 6, 2008, Pages 727-728

  Bai, Ya Mei ^a,b   Chen, Tzu Ting ^c,d   Lin, Wen Kuo ^c   Chang, Wen Ho ^e   Hung, Chih Hung ^c   Chen, Jen Yeu ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; PROLACTIN; RISPERIDONE;

BLOOD SAMPLING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG WITHDRAWAL; HUMAN; HYPERPROLACTINEMIA; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 65949103186     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818de734     Document Type: Letter

References (11)

1. Peng P-W, Huang M-C, Tsai C-J, et al. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection. J Clin Psychopharmacol. 2008;28:726-727.
2. Bai YM, Ting CT, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68: 1218-1225.
3. Byerly MJ, Fisher R, Carmody T, et al. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66:997-1001.
4. Remington G, Kwon J, Collins A, et al. The useofelectronicmonitoring(MEMS)to evaluate antipsychotic compliance in out- patients with schizophrenia. Schizophr Res. 2007;90:229-237.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
6. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20: 121-130.
7. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long- acting injectable risperidone: a 12-month open-label trial of the first long-acting second- generation antipsychotic. J Clin Psychiatry. 2003;64:1250-1257.
8. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70:91-100.
9. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159:133-135.
10. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15:111-117.
11. Bai YM, Wu B, Chen TT, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized schizophrenia patients: 12-week randomized, single-blind study. Pharmacopsychiatry. 2006;39:135-141.